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Abstract
We describe the development of a chemical entity recognition system and its application
in the CHEMDNER-patent track of BioCreative 2015. This community challenge includes
a Chemical Entity Mention in Patents (CEMP) recognition task and a Chemical Passage
Detection (CPD) classification task. We addressed both tasks by an ensemble system that
combines a dictionary-based approach with a statistical one. For this purpose the per-
formance of several lexical resources was assessed using Peregrine, our open-source
indexing engine. We combined our dictionary-based results on the patent corpus with
the results of tmChem, a chemical recognizer using a conditional random field classifier.
To improve the performance of tmChem, we utilized three additional features, viz. part-
of-speech tags, lemmas and word-vector clusters. When evaluated on the training data,
our final system obtained an F-score of 85.21% for the CEMP task, and an accuracy of
91.53% for the CPD task. On the test set, the best system ranked sixth among 21 teams
for CEMP with an F-score of 86.82%, and second among nine teams for CPD with an ac-
curacy of 94.23%. The differences in performance between the best ensemble system
and the statistical system separately were small.
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Introduction
Exploration of the chemical and biological space covered
by patents is essential in the early stages of activities in the
field of medicinal chemistry (1). Analyzing patents can
help to understand compound prior art and to pinpoint al-
ternative starting points for chemical research (2).
Important tasks in patent analysis are the recognition of
chemical names, the identification of chemical structure
images, and the conversion of the extracted names and
images into a structure-searchable form (3). Other types of
entities in medicinal chemistry patents, such as genes and
proteins, diseases, or particular numerical values, may also
be relevant to extract and to relate to chemical entities (4).
The extracted information is often compiled in structured
databases that are easy to query and facilitate computa-
tional analysis.
Usually, patent information is manually extracted (5).
This process is laborious and expensive due to the length
of chemical patent texts, which may take hundreds of
pages, and their complexity (mixture of scientific, technical
and legal language, typographical errors, optical character
recognition errors, etc.). These problems are aggravated by
the sheer number of medicinal chemistry patents (1, 6).
Automatic methods to recognize chemicals in patents can
help to ease this process, but have proven to be elaborate
and demanding (7, 8). One of the impediments is that very
few large annotated gold-standard corpora for algorithm
training and testing are available (9).
The automatic extraction of chemical and biological
data from medicinal chemistry patents was addressed in
the CHEMDNER-patents track of BioCreative V (10). The
track was organized as a community challenge to stimulate
the development and comparative assessment of chemical
and biological entity recognizers, and consisted of three
tasks: (i) Chemical Entity Mention in Patents (CEMP),
focusing on chemical entity recognition in patents; (ii)
Chemical Passage Detection (CPD), focusing on the classi-
fication of patent titles and abstracts according to whether
they contain chemical entities; and (iii) Gene and Protein
Related Object (GPRO), focusing on the recognition of
gene and protein mentions in patents. Our team partici-
pated in the CEMP and CPD tasks.
Previous text-mining research mostly concentrated on
chemical name recognition in scientific literature (4, 11).
Recently, a large-scale patent resource, SureChEMBL (12),
has become available, which contains compounds ex-
tracted from the full-text, images and attachments of pa-
tents, and provides comprehensive search capabilities.
Chemical entity recognition is the first step in the
SureChEMBL data extraction pipeline, but performance
figures have not been presented as yet (12). A variety of
systems to extract chemicals from Medline abstracts were
developed and evaluated as part of the previous
BioCreative IV CHEMDNER task (11). The top-ranking
systems in that challenge used machine-learning techniques
based on conditional random fields (CRFs) (11). However,
some systems that combined dictionary-based and rule-
based approaches also achieved competitive results (13,
14). For the current challenge, we combined a dictionary-
based approach with a statistical, CRF-based approach,
and investigated the performance of the ensemble system




The CHEMDNER-patent corpus (10) was used for the de-
velopment and evaluation of our system. The corpus com-
prises a training corpus of 14 000 manually annotated
patent records (each record consisting of a title and an ab-
stract), divided into a training set and a development set of
7000 records each, and a test set of 40 000 patent records,
of which only 7000 were manually annotated. The annota-
tion process and guidelines were largely similar to the ones
used for the BioCreative IV CHEMDNER corpus, and
have been described extensively (10, 15). Table 1 summar-
izes the number of annotated chemicals and chemical-
related titles and abstracts. Only the annotations of the
training and development sets were made available to the
participants in the challenge. For evaluating the perform-
ance of their system on the test set, teams could submit up
to five runs. To produce the evaluation results, we used the
BioCreative evaluation software (www.biocreative.org/re
sources/biocreative-ii5/evaluation-library/) and focused on
micro-averaged recall, precision and F-score to assess sys-
tem performance for the CEMP task, and on sensitivity
(¼recall), specificity and accuracy for the CPD task. Given
the number of true-positive (TP), false-positive (FP),
false-negative (FN) and true-negative (TN) detections,
these metrics were computed as follows: recall¼TP/
Table 1. Characteristics of the CHEMDNER patent corpus
Training Development Test Total
Patent records 7000 7000 7000 21 000
Manual chemical
annotations
33 543 32 142 33 949 99 634
Unique chemical
annotations
11 977 11 386 11 433 34 796
Chemical-related titles
and abstracts
9152 8937 9270 27 359
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(TPþ FN), precision¼TP/(TPþ FP), F-score¼ 2*preci-
sion*recall/(precisionþ recall), specificity¼TN/(TNþ FP)
and accuracy¼ (TPþTN)/(TPþ FNþFPþTN). We also
used the Markyt prediction analysis toolkit (www.markyt.
org/biocreative/analysis) to visualize the results.
Dictionary-based approach
We used Peregrine, our open-source indexer (16), to ana-
lyze the performance of the different chemical dictionaries.
Tokenization was done with a tokenizer previously de-
veloped by Hettne et al. (17). Term matching was carried
out by partial case-sensitive matching: case-sensitive for
abbreviations (defined as terms of which the majority of
characters consists of capitals and digits), case-insensitive
for all other terms.
Dictionaries
To construct our dictionaries, we selected seven well-
known, publicly available chemical databases covering a
wide range of compounds, namely: Chemical Entities of
Biological Interest (ChEBI) (18), ChEMBL (19), DrugBank
(20), the Human Metabolome Database (HMDB) (21), the
NCGC Pharmaceutical Collection (NPC) (22), PubChem
(23) and the Therapeutic Target Database (TTD) (24). For
each database record, we gathered all chemical terms
(available from possibly different record fields). Chemical
terms were only extracted from records that had associated
chemical structures in the form of MOL files (25). In the
following, we briefly describe the databases and the fields
from which identifiers were extracted.
ChEBI is concerned with molecular entities, focusing on
small chemical compounds (18). It provides an ontological
classification with parent and child relationships. We ex-
tracted data for all three-star (i.e. manually annotated)
compounds from ChEBI SD files. This included synonyms,
ChEBI names, brand names, International Nonproprietary
Names (INNs) and International Union of Pure and
Applied Chemistry (IUPAC) names.
ChEMBL contains information on drug-like bioactive
compounds (19). In addition to literature-derived data,
ChEMBL also contains Food and Drug Administration
(FDA) approved drugs. The data available through
ChEMBL have been manually extracted and standardized
(26). Extracted fields include preferred names, synonyms,
FDA alternative names, INNs, United States Adopted
Names (USANs) and United States Pharmacopoeia (USP)
names.
DrugBank provides information regarding drugs,
including chemical, pharmacological and pharmaceutical
data, and their targets (27). DrugBank data are curated by
a curation team, which relies on primary literature sources.
During production and maintenance, all synonyms and
brand names within DrugBank are extensively reviewed
and only the most common synonyms are kept (20). We
extracted brand names, generic names, synonyms,
Chemical Abstracts Service (CAS) numbers, and IUPAC
names from the DrugBank SD files and DrugCards.
HMDB lists small-molecule metabolites found in the
human body (21). The database links chemical, clinical,
molecular-biology and biochemistry data. HMDB is both
automatically and manually curated (21). All generic
names, synonyms, CAS numbers and IUPAC names were
extracted from the HMDB SD files and MetaboCards.
NPC provides information on clinically approved drugs
from USA, Europe, Canada and Japan for high-throughput
screening (22). We extracted preferred names and syno-
nyms using the NPC browser 1.1.0.
PubChem provides information on the biological activity
of small molecules (23). It consists of three different data-
bases: a compound database, a substance database and a
bioassay database. We extracted structures and all corres-
ponding IUPAC identifiers and synonyms for a subset of
compounds that had structure–activity relationships or
other biological annotations. This subset of compounds was
introduced by Muresan et al. (1) and is the same subset of
PubChem compounds that we used in our previous study on
chemical entity recognition (13). The PubChem compound
database does not contain synonyms. This information is
available through the PubChem substance database. The re-
lations between PubChem substance identifiers (SIDs) and
compound identifiers (CIDs), which have been created by
PubChem through in-house chemical structure standardiza-
tion (23), are specified in the ‘PubChem_CID_associations’
tag available in the downloadable structure data files. We
used the relations between SIDs and CIDs to extract the
synonyms from the substance database and assign them to
the corresponding compounds.
TTD contains information about therapeutic protein
and nucleic acid targets of drugs, corresponding pathways
and targeted diseases (24). All trade names, drug names,
CAS numbers and synonyms were extracted.
Dictionary construction and combination
For each database, a dictionary consisting of the extracted
chemical terms was constructed. Each term was linked to
one or possibly more (in case of ambiguity) compounds,
represented by their MOL files. Dictionaries were com-
bined by merging the identifiers of all compounds in the
dictionaries. To determine which compounds in different
dictionaries were the same, we used the same approach
as in previous studies (28, 29). Briefly, we compared
MOL files by converting them into InChI strings, which
provide unique textual representations of the MOL files.
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Compounds with identical InChI strings were considered
the same, and the corresponding identifiers were merged.
Term exclusion
To improve the precision of the dictionary-based ap-
proach, we applied an exclusion list of terms as previously
described (13). Briefly, the list contains common English
words, like ‘about’, ‘all’ and ‘make’, and ambiguous terms,
such as ‘acid’, ‘crystal’ and ‘lead’. We expanded this list
with exclusion terms mentioned in the annotation guide-
lines for the CEMP task.
We also removed terms that were false-positive detec-
tions in the training data, but only if the ratio of true-posi-
tive to false-positive detections was lower than 0.3. This
threshold was heuristically set based on the training data
in order to prevent erroneous removal of overall correctly
recognized terms because of an occasional false-positive
detection. When testing on the development set, exclusion
ratios were calculated for all false-positive terms in the
training set; when evaluating on the test set, ratios were
computed for all false-positive terms in the combined train-
ing and development sets.
Term inclusion
We identified all missed terms (false negatives) in the train-
ing set and re-indexed the texts for these terms. Only those
terms that, after re-indexing, did not result in false-positive
detections in the training set or had an exclusion ratio
larger than 0.5 were added to the dictionary. When evalu-
ating on the test set, the combined training and develop-
ment sets were used to collect the false negatives and to
determine whether they should be included in the
dictionary.
Machine-learning approach
We used the tmChem chemical recognizer system (30), one
of the best performing systems in the previous BioCreative
CHEMDNER challenge (11). The tmChem system is an
ensemble system that combines the output of two CRF-
based systems. The first system is a modified version of the
BANNER system (31), the second is based on the tmVar
system (32), which employs CRFþþ libraries (https://
taku910.github.io/crfpp/). Previous results of tmChem
showed that the second system outperformed the first as
well as the ensemble system (30). We therefore only used
the second system.
Pre-processing
The tmChem system transliterates non-ASCII Unicode char-
acters to a similar ASCII equivalent. As some non-ASCII
Unicode characters were not handled (causing a system
crash when encountered in text), we expanded the translit-
eration capacities as necessary. We also replaced a vertical
bar enclosed by parentheses or brackets (e.g. [j]), because
these combinations caused tmChem to crash as well.
Features
Our initial feature set consisted of all features extracted by
tmChem, including stemmed words, prefixes and suffixes,
character counts (digit, uppercase, lowercase), semantic
affixes (such as trivial rings) and chemical elements (30).
Three additional types of features were determined
and used to train tmChem: part-of-speech (POS) tags,
lemmas and word-vector clusters. We used the BioC nat-
ural language processing pipeline (33) to generate POS
tags with MaxentTagger (34) and lemmas with
BioLemmatizer (35). Recent studies have shown that fea-
tures based on clusters of word vectors can improve clas-
sification performance (36, 37). We used the word2vec
tool (https://code.google.com/p/word2vec/) to generate
clusters of word vectors. Word2vec employs K-means
clustering. The number of the cluster to which a word be-
longed was taken as a feature.
We generated separate word clusters during the devel-
opment phase and the test phase of the challenge. During
development, the clusters were generated from the 14 000
titles and abstracts in the training and development sets.
These data were extended with 200 full-text chemical pa-
tents that had been used in a previous study (9). We experi-
mented with different numbers of clusters (K¼ 300, 500,
1000). For testing our final system, clusters were generated
using all 54 000 records in the corpus plus the 200 full-text
patents, with K¼ 1000.
Post-processing
For the machine-learning approach, the tmChem post-pro-
cessing steps were applied (30). These include enforcing
tagging consistency (for each term that was found by the
CRF at least twice within an abstract, any term mention in
the abstract that the CRF had not identified was also
tagged), abbreviation resolution (tagging corresponding
abbreviations and long forms), boundary revision (adding
or removing unbalanced brackets or parentheses) and
finding chemical database identifiers (through regular
expressions).
We experimented with different sets of dictionaries for
the dictionary-based approach and different sets of fea-
tures for the machine-learning approach. All terms recog-
nized by the dictionary-based system or the statistical
system were taken as the output of the final ensemble
system.
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Text classification
For the CPD task (classification of patent titles and ab-
stracts as chemical-related or not), we used a straightfor-
ward approach based on the output of the CEMP task. If
our system recognized any chemical term in a text (title or
abstract), the text was categorized as a chemical-related.
Note that the title and abstract of each record were classi-
fied separately.
Results
Table 2 shows the number of compounds and the number
of unique identifiers in the chemical databases. Clearly,
PubChem is by far the largest database. The number of
identifiers that are shared between pairs of databases is
shown in Table 3. Although PubChem contains >90% of
the identifiers in ChEMBL, DrugBank and TTD, the other
databases are much less well covered by PubChem. The
majority of identifiers in DrugBank is covered by NPC and
TTD, but the overlap between all other pairs of databases
is relatively low.
Table 4 shows the performance of the dictionary-based
approach on the development set, with and without use of
the list of exclusion terms. Use of the exclusion list gives a
substantial precision improvement for most dictionaries.
The PubChem dictionary demonstrates the highest recall
among the individual dictionaries, which may be explained
by the large size of the PubChem dictionary and the fact
that it contains the majority of terms from the other dic-
tionaries. The dictionaries from ChEMBL and DrugBank
had the highest precision, which is likely due to the fact
that these databases are highly curated. The low recall of
the dictionaries can be explained by their low coverage of
systematic names and chemical family names. Of the 9194
systematic names that were annotated in the development
corpus, recognition rates ranged from 7.5% for TTD to
53.8% for PubChem (median 31.0%). For family names,
which form the largest annotation group (n¼ 11 710), rec-
ognition rate varied between 3.3% and 20.4% (median
9.1%).
Table 4 also shows the performance of several combin-
ations of dictionaries. As to be expected, the combination
of all dictionaries after term exclusion has the highest re-
call (49%), but the lowest precision (54%). The combin-
ation of dictionaries from ChEBI and HMDB, which we
used in the previous BioCreative CHEMDNER task (13),
gave a recall of 35% and a precision of 78%. The combin-
ation of ChEMBL and DrugBank resulted in the highest
precision (83%).
Table 5 shows the incremental performance of the en-
semble system trained on the training corpus and evaluated
on the development corpus, when different feature sets and
term-processing steps were added. We only present diction-
ary-based results for the combination of ChEMBL and
DrugBank as this combination produced the highest F-score
on the training data when combined with the CRF. For the
CEMP task, all incremental steps improved the F-score, ex-
cept when terms that were missed in the training set were
included in the dictionary. The best ensemble system at-
tained an F-score of 85.21% with a precision of 84.88%
and a recall of 85.55%. For the CPD task, the system that
comprised all processing steps, including the addition of
missed terms, achieved the best performance with an accur-
acy of 91.84% (sensitivity 97.00%, specificity 82.74%).
When we only used the CRF-based system (trained on
all features) to process the development set, we obtained
an F-score of 84.78% (precision 86.14%, recall 83.47%)
on the CEMP task, and an accuracy of 90.96% (sensitivity
94.23%, specificity 85.19%) on the CPD task.
Table 2. Number of compounds and unique identifiers in
chemical databases
Database No. of compounds No. of identifiers
ChEBI 23 240 82 612
ChEMBL 22 245 28 411
DrugBank 6516 31 948
HMDB 40 199 228 907
NPC 14 666 128 153
PubChem 4 235 189 19 049 175
TTD 3196 121 744
Table 3. Number of unique identifiers that overlap between pairs of chemical databases
Database ChEBI ChEMBL DrugBank HMDB NPC PubChem
ChEMBL 1209 (4.3)
DrugBank 2444 (7.6) 3931 (13.8)
HMDB 4885 (5.9) 2293 (8.1) 5946 (18.6)
NPC 3406 (4.1) 6508 (22.9) 23 865 (74.7) 7444 (5.8)
PubChem 45 021 (54.5) 26 251 (92.4) 28 943 (90.6) 52 533 (22.9) 69 873 (54.5)
TTD 4481 (5.4) 4507 (15.9) 18 028 (56.4) 6503 (5.3) 23 901 (19.6) 119 819 (98.4)
The percentage coverage of the identifiers in the smallest sized database of each pair is given in parentheses.
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Table 6 shows the performance for both tasks on the
test set. We submitted runs of the ensemble systems with
and without the addition of missed terms. For comparison,
we also submitted a run for the statistical system alone
(including all features and post-processing).
For the CEMP task, the statistical system performed
best (F-score 86.82%), slightly better than the ensemble
system without the addition of missed terms (F-score
86.55%). For CPD, the ensemble system with missed terms
reached the best performance (accuracy 94.23%), slightly
better again than the system without missed terms
(93.93%). Our best systems ranked sixth among 21 partic-
ipating teams for the CEMP task, and second among nine
teams for the CPD task.
Discussion
We investigated the combination of dictionary-based and
statistical approaches for chemical entity recognition in pa-
tents. Our results show that the recall of the chemical dic-
tionaries on the CEMP task is low, and even a combination
of all dictionaries gives a recall and precision of only around
50%. The low recall can be explained by the fact that many
systematic chemical terms and chemical family names were
lacking in our lexical resources. Meanwhile, the machine-
learning approach yielded a much higher precision and re-
call (86% and 83%, respectively). In order to maintain the
high precision of the ensemble system, we used the diction-
ary combination with the highest precision (ChEMBL and
DrugBank). For the CEMP task, this supplied us with a
Table 4. Performance of different dictionaries and dictionary combinations with and without removal of exclusion terms
Without exclusion With exclusion
Dictionary Precision Recall F-score Precision Recall F-score
ChEBI 56.51 29.47 38.74 78.87 28.42 41.79
ChEMBL 84.53 20.46 32.94 85.11 19.87 32.22
DrugBank 68.20 17.28 27.58 85.15 16.89 28.19
HMDB 66.11 29.38 40.68 79.59 28.19 41.63
NPC 30.90 44.85 36.59 55.23 30.61 39.39
TTD 66.89 14.07 23.24 80.90 13.89 23.71
PubChem 34.30 47.11 39.69 67.03 45.64 54.30
All combined 30.85 50.32 38.25 53.66 48.59 51.00
ChEBI–HMDB 55.46 36.98 44.37 78.12 35.45 48.77
ChEMBL–DrugBank 70.51 23.94 35.74 83.02 23.16 36.21
Table 5. Performance of the ensemble system trained on the training set and tested on the development set
CEMP task CPD task
System Precision Recall F-score Sensitivity Specificity Accuracy
Dictionary-based (ChEMBL-DrugBank) 70.51 23.94 35.74 50.63 88.41 64.29
þ Exclusion list 83.02 23.16 36.21 44.29 94.37 62.40
þ Term removal (exclusion ratio 0.3) 88.85 23.09 36.65 42.14 97.12 62.02
þ CRF original features 84.96 83.83 84.39 95.11 85.33 91.57
þ Post-processing (CRF) 84.50 84.91 84.70 95.39 85.01 91.64
þ POS and lemmatization features 84.72 85.09 84.90 95.40 85.25 91.73
þWord-vector cluster features 84.88 85.55 85.21 95.31 84.87 91.54
þMissed terms (exclusion ratio 0.5) 75.88 88.63 81.76 97.00 82.74 91.84
Table 6. Performance of different systems on the test set
CEMP task CPD task
System Precision Recall F-score Sensitivity Specificity Accuracy
Statistical 86.83 86.81 86.82 96.13 88.67 93.61
Statistical þ dictionary without missed terms 84.92 88.25 86.55 97.00 87.91 93.93
Statistical þ dictionary with missed terms 77.76 90.84 83.79 98.03 86.79 94.23
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system that slightly improved machine-learning perform-
ance on the development set, but not on the test set. Thus,
there was no performance gain for this task by the use of a
combined dictionary-based and statistical approach over a
statistical approach alone. For the CPD task, the ensemble
system performed better than the statistical system alone,
both on the development set and on the test set. This may
be explained by the 1.9 percentage point higher sensitivity
of the ensemble system, in combination with a similar de-
crease in specificity. As the majority of titles and abstracts in
the development and test sets are chemical-related (see
Table 2), sensitivity weighs more heavily than specificity in
the accuracy. For both tasks, our results on the test set were
better than those on the development set, indicating that
overtraining did not occur.
Contrary to our expectation, the inclusion of false-nega-
tive terms in the dictionary decreased the performance for
the CEMP task, both on the development set and on the test
set. This may partly be explained by tokenization issues that
split chemical terms in multiple parts. Some of these parts
were then erroneously matched with the newly added dic-
tionary terms, resulting in a drop in precision. For the CPD
task, the increase in sensitivity more than compensated for
the decrease in specificity, yielding a slightly improved ac-
curacy of the ensemble system using the missed terms.
Although furnishing structure information about the
recognized chemicals was not part of the challenge, this in-
formation is often important in practical applications. We
are able to readily associate dictionary terms with struc-
tures because we only extracted terms from chemical re-
cords with structure information. Of the chemical terms in
the development set, 23% is found by the dictionary-based
approach and can be linked to structures. For the machine-
learning approach, the mapping of recognized terms to
structures is less straightforward, but part of these terms
will consist of systematic chemical identifiers. These can
also be converted into chemical structures using chemical
naming conversion software (28, 29).
Considering that annotated patent corpora are scarce, the
CHEMDNER corpus of annotated patent titles and abstracts
is a highly valuable and important resource for further devel-
opment and comparative assessment of algorithms. Recently,
we have reported on the creation of another corpus of 200
annotated full-text patents, which is publicly available (9).
We plan to use this corpus to evaluate and possibly improve
the performance of our systems on full-text patents.
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